title: Pharmacodynamic characteristics of low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction.
abstract: Sixteen patients (5 female and 11 male, mean age 59.1 years) who had had an acute myocardial infarction within the previous 7 days, were enrolled in an open pharmacodynamic study. Patients were randomly allocated to two treatment groups and given a single subcutaneous dose of 100 or 200 mg of a new low-molecular-weight dermatan sulphate. The drug pharmacodynamic profile was determined 1, 2, 4, 6, 8, 12 and 24 h after administration. The following coagulation and fibrinolysis tests were performed: activated partial thromboplastin time, thrombin time, activated factor X inhibition, Heptest (global clotting time), heparin cofactor II affinity, functional and antigenic plasminogen activator inhibitor and fibrin plate assay. Both Heptest and heparin cofactor II affinity were significantly increased (P < 0.001) in a dose-dependent manner. The XaI was enhanced, though to a lesser extent. None of the other coagulation or fibrinolysis tests showed significant changes at either dose. Systemic and local tolerance were always very good.
authors.affiliation: Institute of Cardiovascular Diseases, University of Bologna, Italy.
authors.forename: A M
authors.initials: AM
authors.lastname: Traini
authors.forename: V
authors.initials: V
authors.lastname: Cervi
authors.forename: G
authors.initials: G
authors.lastname: Melandri
authors.forename: E
authors.initials: E
authors.lastname: Palazzini
authors.forename: V
authors.initials: V
authors.lastname: Zamboni
authors.forename: F
authors.initials: F
authors.lastname: Semprini
authors.forename: N
authors.initials: N
authors.lastname: Candiotti
authors.forename: A
authors.initials: A
authors.lastname: Branzi
mesh_terms: D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D001780:Blood Coagulation Tests; D003871:Dermatan Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D065427:Factor Xa Inhibitors; D005260:Female; D005337:Fibrin / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D015844:Heparin Cofactor II / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D009203:Myocardial Infarction / Q000188:drug therapy*; D015849:Plasminogen Inactivators / Q000097:blood; D011517:Prothrombin Time; D013918:Thrombin Time; D013997:Time Factors
chemical_list: D065427:Factor Xa Inhibitors; D015849:Plasminogen Inactivators; D003871:Dermatan Sulfate; D015844:Heparin Cofactor II; D005337:Fibrin